{"DataElement":{"publicId":"6304232","version":"1","preferredName":"Prior Clinical Study Protocol Therapeutic Procedure Name","preferredDefinition":"The name of a substance previously delivered to a patient/participant as part of a clinical trial regimen or plan.","longName":"6304231v1.0:6304225v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"6304231","version":"1","preferredName":"Prior Clinical Study Protocol Therapeutic Procedure Name","preferredDefinition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents._Earlier in time or order._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The words or language units by which a thing is known.","longName":"2206612v1.0:6304229v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"2206612","version":"1","preferredName":"Prior Protocol","preferredDefinition":"Earlier in time or order.:An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.","longName":"C25629:C25320","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FC57-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6304229","version":"1","preferredName":"Therapeutic Procedure Name","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:The words or language units by which a thing is known.","longName":"C49236:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D5748F7-7244-128C-E053-F662850A4C05","latestVersionIndicator":"Yes","beginDate":"2018-05-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-29","modifiedBy":"ONEDATA","dateModified":"2018-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D5748F7-7255-128C-E053-F662850A4C05","latestVersionIndicator":"Yes","beginDate":"2018-05-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-29","modifiedBy":"MORENOC","dateModified":"2018-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6304225","version":"1","preferredName":"Prior Protocol Treatment Name","preferredDefinition":"The name of the prior protocol treatment.","longName":"6304225v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Placebo","valueDescription":"Placebo","ValueMeaning":{"publicId":"3228305","version":"1","preferredName":"Placebo","longName":"3228305","preferredDefinition":"An inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15C7F84-4B5D-4B63-E040-BB89AD432192","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6D571E6D-F758-6DE5-E053-F662850AF8F4","beginDate":"2018-05-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-29","modifiedBy":"ONEDATA","dateModified":"2018-05-29","deletedIndicator":"No"},{"value":"Fosaprepitant","valueDescription":"Fosaprepitant Dimeglumine","ValueMeaning":{"publicId":"6304228","version":"1","preferredName":"Fosaprepitant Dimeglumine","longName":"6304228","preferredDefinition":"The dimeglumine salt form of fosaprepitant, the water-soluble, N-phosphorylated prodrug of aprepitant, with antiemetic activity. Upon intravenous administration and rapid conversion to aprepitant, this agent binds selectively to the human substance P/neurokinin 1 (NK1) receptors in the central nervous system (CNS). This inhibits receptor binding of the endogenous substance P and prevents substance P-induced emesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fosaprepitant Dimeglumine","conceptCode":"C72788","definition":"The dimeglumine salt form of fosaprepitant, the water-soluble, N-phosphorylated prodrug of aprepitant, with antiemetic activity. Upon intravenous administration and rapid conversion to aprepitant, this agent binds selectively to the human substance P/neurokinin 1 (NK1) receptors in the central nervous system (CNS). This inhibits receptor binding of the endogenous substance P and prevents substance P-induced emesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D571E6D-F735-6DE5-E053-F662850AF8F4","latestVersionIndicator":"Yes","beginDate":"2018-05-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-29","modifiedBy":"ONEDATA","dateModified":"2018-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6D571E6D-F74E-6DE5-E053-F662850AF8F4","beginDate":"2018-05-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-29","modifiedBy":"ONEDATA","dateModified":"2018-05-29","deletedIndicator":"No"},{"value":"Fosaprepitant/Aprepitant","valueDescription":"Fosaprepitant Dimeglumine Aprepitant","ValueMeaning":{"publicId":"6841501","version":"1","preferredName":"Fosaprepitant Dimeglumine Aprepitant","longName":"6841501","preferredDefinition":"The dimeglumine salt form of fosaprepitant, the water-soluble, N-phosphorylated prodrug of aprepitant, with antiemetic activity. Upon intravenous administration and rapid conversion to aprepitant, this agent binds selectively to the human substance P/neurokinin 1 (NK1) receptors in the central nervous system (CNS). This inhibits receptor binding of the endogenous substance P and prevents substance P-induced emesis.: A small molecule, high-affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively to the human substance P/neurokinin 1 receptor in the central nervous system (CNS), thereby inhibiting receptor binding of endogenous substance P and substance P-induced emesis. This agent has little or no affinity for serotonin type 3 (5-HT3), dopamine, and corticosteroid receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fosaprepitant Dimeglumine","conceptCode":"C72788","definition":"The dimeglumine salt form of fosaprepitant, the water-soluble, N-phosphorylated prodrug of aprepitant, with antiemetic activity. Upon intravenous administration and rapid conversion to aprepitant, this agent binds selectively to the human substance P/neurokinin 1 (NK1) receptors in the central nervous system (CNS). This inhibits receptor binding of the endogenous substance P and prevents substance P-induced emesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Aprepitant","conceptCode":"C49173","definition":"A small molecule, high-affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively to the human substance P/neurokinin 1 receptor in the central nervous system (CNS), thereby inhibiting receptor binding of endogenous substance P and substance P-induced emesis. This agent has little or no affinity for serotonin type 3 (5-HT3), dopamine, and corticosteroid receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EF7AFD4-22BC-27C3-E053-F662850AFC86","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8EF7AFD4-22D5-27C3-E053-F662850AFC86","beginDate":"2019-07-31","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","deletedIndicator":"No"},{"value":"Placebo 5.0 mL","valueDescription":"Placebo 5.0 mL","ValueMeaning":{"publicId":"7636180","version":"1","preferredName":"Placebo 5.0 mL","longName":"7636180","preferredDefinition":"Placebo 5.0 mL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFF3EC49-47D8-50F9-E053-4EBD850A158C","latestVersionIndicator":"Yes","beginDate":"2021-04-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2021-04-14","modifiedBy":"ONEDATA","dateModified":"2021-04-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BFF3EC49-47F1-50F9-E053-4EBD850A158C","beginDate":"2021-04-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2021-04-14","modifiedBy":"ONEDATA","dateModified":"2021-04-14","deletedIndicator":"No"},{"value":"Placebo 2.5 mL","valueDescription":"Placebo 2.5 mL","ValueMeaning":{"publicId":"7636181","version":"1","preferredName":"Placebo 2.5 mL","longName":"7636181","preferredDefinition":"Placebo 2.5 mL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFF3EC49-47FB-50F9-E053-4EBD850A158C","latestVersionIndicator":"Yes","beginDate":"2021-04-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2021-04-14","modifiedBy":"ONEDATA","dateModified":"2021-04-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BFF3EC49-4814-50F9-E053-4EBD850A158C","beginDate":"2021-04-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2021-04-14","modifiedBy":"ONEDATA","dateModified":"2021-04-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D571E6D-F70E-6DE5-E053-F662850AF8F4","latestVersionIndicator":"Yes","beginDate":"2018-05-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-29","modifiedBy":"MORENOC","dateModified":"2021-04-14","changeDescription":"11/14/2018: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Previous protocol treatment","type":"Preferred Question Text","description":"Previous protocol treatment","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D5780FF-1772-1336-E053-F662850AA596","latestVersionIndicator":"Yes","beginDate":"2018-05-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-29","modifiedBy":"MORENOC","dateModified":"2018-11-14","changeDescription":"11/14/2018: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}